Astellas Enters Exclusive License Agreement with Evopoint Biosciences for CLDN18.2-targeting ADC XNW27011 June 3, 2025
Statistically Significant Topline Results from Global Ph 2 Trial of Elraglusib in 1L Treatment of Metastatic Pancreatic Cancer Announced May 13, 2025
Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Ph 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in 1L Metastatic Pancreatic Cancer Patients May 13, 2025
IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers May 13, 2025
Full Results Announced From Completed Ph 1 Study of JNJ-1900 (NBTXR3) in Pancreatic Cancer May 6, 2025
FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient March 26, 2025
Positive Topline Result for TEDOPaM Ph 2 trial of OSE2101 (Tedopi) in Advanced Pancreatic Cancer Announced March 18, 2025
EU authorises CTA to initiate VIDAR-1 Ph 1/2 umbrella trial in patients with mutated KRAS-positive advanced pancreatic cancer March 18, 2025
First New Subject Dosed in Ph 2 Study of Ampligen and Imfinzi Combination Therapy for Late-Stage Pancreatic Cancer March 4, 2025
Positive Final Survival Data from Ph 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Announced March 4, 2025
FDA RMAT Designation for CAR-NK in Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer March 4, 2025
Go-ahead obtained to continue enrolling patients in its pancreatic cancer trial (GOBLET Cohort 5) after a positive safety review February 25, 2025
Positive Topline Results of Ph 3 COMPETE Trial with ITM-11 in Patients with Gr 1 or 2 GEP-NETs announced February 4, 2025
Positive interim Alpha DaRT data from multiple clinical trials in pancreatic cancer, a combination study with pembrolizumab in patients with recurrent unresectable or metastatic HNSCC, and other clinical trials announced February 4, 2025
ASCO GI 2025: Preliminary Cohort A Data from Ph 2 ASCEND Trial of Certepetide with SOC Chemo in Metastatic Pancreatic Ductal Adenocarcinoma reported January 28, 2025
Positive Update provided on Ph 2a Arm of IMM-1-104 in Combination with Modified FOLFIRINOX for 1L Pancreatic Cancer January 15, 2025
Supplemental NDA for cabozantinib in pNET and epNET patients no longer the subject of discussion at an ODAC meeting January 15, 2025
ELC-100 receives Orphan Drug Designation in the U.S. for the treatment of pancreatic neuroendocrine tumors January 15, 2025
Positive Interim Ph 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer Announced December 26, 2024
Marker Therapeutics Awarded $9.5 Million Grant from the CPRIT to Support the Investigation of MT-601 in Patients with Pancreatic Cancer December 26, 2024
Outcomes of Type D meeting with FDA to obtain guidance on the design of a Ph 3 study of VCN-01 + chemo in metastatic pancreatic adenocarcinoma (PDAC) announced December 10, 2024
